-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Parkinson's disease (PD) is a common neurodegenerative disease.
The clinical manifestations mainly include resting tremor, bradykinesia, rigidity and postural gait disturbance, and can be accompanied by depression, constipation and Non-motor symptoms such as sleep disturbances usually bring huge physical and mental burdens to patients and their families
.
According to incomplete statistics, there are about 10 million Parkinson's disease patients in the world, and the number is still rising
.
At present, the treatment of Parkinson's disease is mainly symptomatic treatment based on symptom control.
The specific methods mainly include drug therapy and surgical treatment.
Others also involve gene therapy, rehabilitation training and diet therapy
.
In recent years, based on the huge patient population and treatment needs, many pharmaceutical companies have begun to deploy in this field
.
The author learned that with the efforts of many pharmaceutical companies, more than 50 PD drugs have been approved for marketing in the world
.
According to different mechanisms of action, the marketed PD drugs can be roughly divided into anticholinergic drugs, dopamine-promoting drugs, dopamine replacement drugs, dopamine receptor agonists, B-type monoamine oxidase inhibitors, catechol-O-methyl There are six classes of transferase (COMT) inhibitors
.
It is worth noting that, according to a market research report by MarketsandMarkets, the global PD therapeutics market size in 2022 is expected to grow from $4.
24 billion in 2017 to $5.
69 billion in 2022, with a compound annual growth rate of 6.
1%
.
In this context, more and more pharmaceutical companies have begun to notice the potential of the PD market and are actively deploying the PD drug market
.
It is reported that this year, many pharmaceutical companies and other companies have been jointly developing or introducing new PD treatments
.
For example, recently, the CDE website showed that the import application of ZambonS.
pA/Jingding Pharmaceutical's "Safinamide Tablets" was accepted
.
According to public information, safinamide is a highly selective and reversible third-generation B-type monoamine oxidase (MAO-B) inhibitor with dual dopaminergic and non-dopaminergic mechanisms.
The original drug Xadago was approved by the FDA in March 2017.
As an add-on therapy for patients with Parkinson's disease who are taking levodopa/carbidopa and have "off" episodes
.
The industry believes that the submission of Safinamide Tablets for listing in China this time is expected to bring new options for innovative therapies and drugs to domestic patients
.
In addition, in March 2022, Yisi Bio also signed an exclusive license agreement with BRITANNIA, a British company under the STADA Group, to obtain the latter's apomorphine subcutaneous injection for the treatment of PD in mainland China, Hong Kong and Macau.
commercialization rights
.
On the whole, the huge consumer group and the improvement of the consumption capacity of anti-Parkinson's disease drugs will bring more new development opportunities to the global anti-Parkinson's disease drug industry, and the future market prospects are good
.
However, due to the large number of anti-Parkinson's disease drugs and high barriers to entry, the current situation of high foreign dependence on most domestic drugs will also pose certain challenges for domestic pharmaceutical companies to enter the anti-Parkinson's disease drug market.
There is still a long way to go for enterprises to find innovative treatments for PD
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The clinical manifestations mainly include resting tremor, bradykinesia, rigidity and postural gait disturbance, and can be accompanied by depression, constipation and Non-motor symptoms such as sleep disturbances usually bring huge physical and mental burdens to patients and their families
.
According to incomplete statistics, there are about 10 million Parkinson's disease patients in the world, and the number is still rising
.
At present, the treatment of Parkinson's disease is mainly symptomatic treatment based on symptom control.
The specific methods mainly include drug therapy and surgical treatment.
Others also involve gene therapy, rehabilitation training and diet therapy
.
In recent years, based on the huge patient population and treatment needs, many pharmaceutical companies have begun to deploy in this field
.
The author learned that with the efforts of many pharmaceutical companies, more than 50 PD drugs have been approved for marketing in the world
.
According to different mechanisms of action, the marketed PD drugs can be roughly divided into anticholinergic drugs, dopamine-promoting drugs, dopamine replacement drugs, dopamine receptor agonists, B-type monoamine oxidase inhibitors, catechol-O-methyl There are six classes of transferase (COMT) inhibitors
.
It is worth noting that, according to a market research report by MarketsandMarkets, the global PD therapeutics market size in 2022 is expected to grow from $4.
24 billion in 2017 to $5.
69 billion in 2022, with a compound annual growth rate of 6.
1%
.
In this context, more and more pharmaceutical companies have begun to notice the potential of the PD market and are actively deploying the PD drug market
.
It is reported that this year, many pharmaceutical companies and other companies have been jointly developing or introducing new PD treatments
.
For example, recently, the CDE website showed that the import application of ZambonS.
pA/Jingding Pharmaceutical's "Safinamide Tablets" was accepted
.
According to public information, safinamide is a highly selective and reversible third-generation B-type monoamine oxidase (MAO-B) inhibitor with dual dopaminergic and non-dopaminergic mechanisms.
The original drug Xadago was approved by the FDA in March 2017.
As an add-on therapy for patients with Parkinson's disease who are taking levodopa/carbidopa and have "off" episodes
.
The industry believes that the submission of Safinamide Tablets for listing in China this time is expected to bring new options for innovative therapies and drugs to domestic patients
.
In addition, in March 2022, Yisi Bio also signed an exclusive license agreement with BRITANNIA, a British company under the STADA Group, to obtain the latter's apomorphine subcutaneous injection for the treatment of PD in mainland China, Hong Kong and Macau.
commercialization rights
.
On the whole, the huge consumer group and the improvement of the consumption capacity of anti-Parkinson's disease drugs will bring more new development opportunities to the global anti-Parkinson's disease drug industry, and the future market prospects are good
.
However, due to the large number of anti-Parkinson's disease drugs and high barriers to entry, the current situation of high foreign dependence on most domestic drugs will also pose certain challenges for domestic pharmaceutical companies to enter the anti-Parkinson's disease drug market.
There is still a long way to go for enterprises to find innovative treatments for PD
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
